Updated analysis of HERBIS-1: A phase ll study of trastuzumab (T-mab) in combination with tri-weekly S-1 plus CDDP in HER2-positive advanced gastric cancer.
Makio Gamoh
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Naotoshi Sugimoto
Honoraria - Osaka GI-Cancer meeting
Research Funding - The meeting of HER-2 positive gastric cancer
Hiroto Miwa
No relevant relationships to disclose
Masahiro Tsuda
No relevant relationships to disclose
Shinichi Nishina
No relevant relationships to disclose
Hiroyuki Okuda
No relevant relationships to disclose
Hiroshi Imamura
No relevant relationships to disclose
Jin Matsuyama
No relevant relationships to disclose
Toshio Shimokawa
No relevant relationships to disclose
Daisuke Sakai
No relevant relationships to disclose
Yukinori Kurokawa
Honoraria - Chugai Pharma; Taiho Pharmaceutical
Yoshito Komatsu
Honoraria - Chugai Pharma; Otsuka; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Otsuka; Taiho Pharmaceutical
Toshimasa Tsujinaka
Honoraria - Taiho Pharmaceutical
Chikashi Ishioka
Honoraria - Taiho Pharmaceutical
Research Funding - Chugai Pharma; Taiho Pharmaceutical
Hiroshi Furukawa
No relevant relationships to disclose